GlassScriptPhysician profile
Charles A Thayer
NPI 1306871454
$2,715.83
in general payments reported to CMS, 2019-2025
28 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $212 · 2021: $584 · 2022: $468 · 2023: $617 · 2024: $333 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $459.57 | 2019-2025 | Stravix, Collagenase Santyl, Iodosorb Ointment 40g USA |
| Gilead Sciences, INC. | $296.07 | 2021-2023 | Veklury |
| Kerecis Limited | $239.89 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Abbvie INC. | $187.31 | 2022-2024 | Dalvance, Teflaro, Avycaz |
| Viiv Healthcare Company | $149.29 | 2020-2024 | Apretude |
| Tela Bio, INC. | $145.80 | 2020-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Paratek Pharmaceuticals, INC. | $138.26 | 2023-2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $130.20 | 2020-2024 | Zerbaxa, Dificid, Delstrigo |
| Convatec INC. | $121.25 | 2019-2021 | |
| Janssen Biotech, INC. | $110.68 | 2023 | Symtuza |
| Ethicon US, LLC | $96.45 | 2019-2024 | Ethicon |
| Janssen Pharmaceuticals, INC | $68.38 | 2021-2022 | |
| Cook Medical LLC | $59.99 | 2019 | |
| Integra Lifesciences Corporation | $58.98 | 2021-2022 | |
| Kci USA, INC. | $58.05 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $49.31 | 2021-2023 | Xerava |
| Medtronic, INC. | $46.95 | 2023 | Dextile |
| Tei Biosciences INC | $42.17 | 2019 | |
| Misonix INC | $38.85 | 2019-2021 | |
| Teleflex LLC | $32.66 | 2022 | |
| Astellas Pharma US INC | $31.49 | 2021 | |
| Medtronic Vascular, INC. | $27.23 | 2019-2020 | |
| Covidien LP | $23.82 | 2019 | |
| Allergan, INC. | $23.73 | 2020 | |
| Lifenet Health | $23.51 | 2024 | Theragenesis Wound Matrix |
| Organogenesis INC. | $21.28 | 2024 | Puraply Franchise |
| Polynovo North America LLC | $19.62 | 2024 | Novosorb Btm |
| Osiris Therapeutics INC. | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Thayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.